These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 24131304)

  • 1. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.
    Scheerens H; Arron JR; Zheng Y; Putnam WS; Erickson RW; Choy DF; Harris JM; Lee J; Jarjour NN; Matthews JG
    Clin Exp Allergy; 2014 Jan; 44(1):38-46. PubMed ID: 24131304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
    Austin CD; Gonzalez Edick M; Ferrando RE; Solon M; Baca M; Mesh K; Bradding P; Gauvreau GM; Sumino K; FitzGerald JM; Israel E; Bjermer L; Bourdin A; Arron JR; Choy DF; Olsson JK; Abreu F; Howard M; Wong K; Cai F; Peng K; Putnam WS; Holweg CTJ; Matthews JG; Kraft M; Woodruff PG;
    Clin Exp Allergy; 2020 Dec; 50(12):1342-1351. PubMed ID: 32909660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lebrikizumab treatment in adults with asthma.
    Corren J; Lemanske RF; Hanania NA; Korenblat PE; Parsey MV; Arron JR; Harris JM; Scheerens H; Wu LC; Su Z; Mosesova S; Eisner MD; Bohen SP; Matthews JG
    N Engl J Med; 2011 Sep; 365(12):1088-98. PubMed ID: 21812663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.
    Noonan M; Korenblat P; Mosesova S; Scheerens H; Arron JR; Zheng Y; Putnam WS; Parsey MV; Bohen SP; Matthews JG
    J Allergy Clin Immunol; 2013 Sep; 132(3):567-574.e12. PubMed ID: 23726041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OX40L blockade and allergen-induced airway responses in subjects with mild asthma.
    Gauvreau GM; Boulet LP; Cockcroft DW; FitzGerald JM; Mayers I; Carlsten C; Laviolette M; Killian KJ; Davis BE; Larché M; Kipling C; Dua B; Mosesova S; Putnam W; Zheng Y; Scheerens H; McClintock D; Matthews JG; O'Byrne PM
    Clin Exp Allergy; 2014 Jan; 44(1):29-37. PubMed ID: 24224471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.
    Korenblat P; Kerwin E; Leshchenko I; Yen K; Holweg CTJ; Anzures-Cabrera J; Martin C; Putnam WS; Governale L; Olsson J; Matthews JG
    Respir Med; 2018 Jan; 134():143-149. PubMed ID: 29413502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
    Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
    Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial.
    Beeh KM; Beier J; Meyer M; Buhl R; Zahlten R; Wolff G
    Pulm Pharmacol Ther; 2006; 19(4):233-41. PubMed ID: 16140027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma.
    Liu Y; Zhang S; Chen R; Wei J; Guan G; Zhou M; Dong N; Cao Y
    Allergy Asthma Proc; 2018 Sep; 39(5):332-337. PubMed ID: 30153886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.
    Hanania NA; Noonan M; Corren J; Korenblat P; Zheng Y; Fischer SK; Cheu M; Putnam WS; Murray E; Scheerens H; Holweg CT; Maciuca R; Gray S; Doyle R; McClintock D; Olsson J; Matthews JG; Yen K
    Thorax; 2015 Aug; 70(8):748-56. PubMed ID: 26001563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma.
    Leaker BR; Barnes PJ; O'Connor BJ; Ali FY; Tam P; Neville J; Mackenzie LF; MacRury T
    Clin Exp Allergy; 2014 Sep; 44(9):1146-53. PubMed ID: 25040039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab in persistent asthma with elevated eosinophil levels.
    Wenzel S; Ford L; Pearlman D; Spector S; Sher L; Skobieranda F; Wang L; Kirkesseli S; Rocklin R; Bock B; Hamilton J; Ming JE; Radin A; Stahl N; Yancopoulos GD; Graham N; Pirozzi G
    N Engl J Med; 2013 Jun; 368(26):2455-66. PubMed ID: 23688323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.
    Diamant Z; Sidharta PN; Singh D; O'Connor BJ; Zuiker R; Leaker BR; Silkey M; Dingemanse J
    Clin Exp Allergy; 2014 Aug; 44(8):1044-52. PubMed ID: 24964348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study.
    Siddall H; Quint D; Pandya H; Powley W; Shabbir S; Hohlfeld JM; Singh D; Lee L
    PLoS One; 2020; 15(11):e0240964. PubMed ID: 33166307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population.
    Corren J; Szefler SJ; Sher E; Korenblat P; Soong W; Hanania NA; Berman G; Brusselle G; Zitnik R; Natalie CR; Sun L; Siu K; Wu WS; Lio P; Armstrong AW
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1215-1224.e3. PubMed ID: 38360213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lebrikizumab in the personalized management of asthma.
    Thomson NC; Patel M; Smith AD
    Biologics; 2012; 6():329-35. PubMed ID: 23055690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.
    Wenzel S; Wilbraham D; Fuller R; Getz EB; Longphre M
    Lancet; 2007 Oct; 370(9596):1422-31. PubMed ID: 17950857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The late asthmatic response is associated with baseline allergen-specific proliferative responsiveness of peripheral T lymphocytes in vitro and serum interleukin-5.
    van der Veen MJ; Van Neerven RJ; De Jong EC; Aalberse RC; Jansen HM; van der Zee JS
    Clin Exp Allergy; 1999 Feb; 29(2):217-27. PubMed ID: 10051726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.
    Krug N; Hohlfeld JM; Kirsten AM; Kornmann O; Beeh KM; Kappeler D; Korn S; Ignatenko S; Timmer W; Rogon C; Zeitvogel J; Zhang N; Bille J; Homburg U; Turowska A; Bachert C; Werfel T; Buhl R; Renz J; Garn H; Renz H
    N Engl J Med; 2015 May; 372(21):1987-95. PubMed ID: 25981191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
    Zhu R; Zheng Y; Dirks NL; Vadhavkar S; Jin JY; Peng K; Holweg CTJ; Olsson J; Matthews JG; Putnam WS
    Pulm Pharmacol Ther; 2017 Oct; 46():88-98. PubMed ID: 28843617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.